Literature DB >> 646294

Clinical significance of rebound nystagmus in neuro-otological diagnosis.

C Morales-Garcia, J L Cardenas, C Arriagada, J Otte.   

Abstract

The present study is concerned with a clinical analysis of 17 patients with "rebound nystagmus" examined over a period of three years. All of them have shown a short duration second degree nystagmus evoked by changes in the direction of fixation, from the lateral to straight ahead gaze. This nystagmus was a fixation nystagmus, that is to say, it was enhanced in the presence of active optic fixation and inhibited in its absence. Almost all the patients (16 out of 17) had cerebellar signs on neurological examination (in one subject rebound nystagmus was the first sign suggesting cerebellar involvement and appeared several months before any other cerebellar sign was present). Rebound nystagmus was far more common than the other neuro-otological signs suggesting cerebellar dysfunction (vestibular hyperexcitability, dysrhythmia in postcaloric nystagmus and ocular dysmetria). In three out of four patients with unilateral lesions rebound nystagmus was ipsilateral with respect to the side of the lesion. Postmortem studies were carried out upon five cases and showed either pathological changes in the cerebellum or a lesion involving the cerebellar peduncles in the brain stem.

Entities:  

Mesh:

Year:  1978        PMID: 646294     DOI: 10.1177/000348947808700216

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  2 in total

1.  Keeping your head on target.

Authors:  Aasef G Shaikh; Aaron L Wong; David S Zee; H A Jinnah
Journal:  J Neurosci       Date:  2013-07-03       Impact factor: 6.167

2.  Cerebellar Rebound Nystagmus Explained as Gaze-Evoked Nystagmus Relative to an Eccentric Set Point: Implications for the Clinical Examination.

Authors:  Giovanni Bertolini; Alexander A Tarnutzer; Stefan Yu Bögli; Dominik Straumann; Bernhard Schuknecht
Journal:  Cerebellum       Date:  2021-10       Impact factor: 3.847

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.